17.3 USING RASCH ANALYSIS TO IDENTIFY NEGATIVE SYMPTOM RESPONSE TRAJECTORIES IN FIRST-EPISODE SCHIZOPHRENIA

摘要

The negative symptom domain is considered a core feature of schizophrenia and a prognostic marker of functional outcome. Amisulpride is characterized by selective and high affinity for dopamine (D2/D3) receptors, preferentially in limbic structures. Its special mode of action gives amisulpride a theoretical potential for treatment of negative symptoms, which has been confirmed empirically but with immense variation in treatment response between subjects. We lack knowledge of a more detailed understanding of this observed heterogeneity in negative symptom treatment response.